Citius pharmaceuticals, inc. announces positive recommendation by independent data monitoring committee to continue the mino-lok® phase 3 trial as planned

Cranford, n.j., july 1, 2021 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that following a unblinded data review of safety and efficacy, the independent data monitoring committee (dmc) for the mino-lok® phase 3 pivotal superiority trial has recommended proceeding with the trial as planned.
CTXR Ratings Summary
CTXR Quant Ranking